Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

LianBio LIAN NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
33/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

LianBio (LIAN) is a Biotechnology company in the Healthcare sector, currently trading at $0.32. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $110M (loss), growing at -156.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $260M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 13.24 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $320M.

Analyst outlook: 1 / 3 analysts rate LIAN as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

LIAN SharesGrow Score Overview

41/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LIAN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
LIAN: +0%/yr revenue is, -156.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LIAN: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 13.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
LIAN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 1 / 3 analysts rate LIAN as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.2787-0.3498
Volume2.48M
Avg Volume (30D)146.63K
Market Cap$34.47M
Beta (1Y)0.23
Dividend Yield$0.4300
Share Statistics
EPS (TTM)-1.02
Shares Outstanding$107.92M
IPO Date2021-11-01
Employees163
CEOAdam Leo Stone
Financial Highlights & Ratios
Gross Profit$-1M
EBITDA$-124.35M
Net Income$-110.29M
Operating Income$-125.35M
Total Cash$302.36M
Total Debt$4.34M
Net Debt$-74.88M
Total Assets$319.96M
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering3
Buy 33% Hold 33% Sell 33%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS53000N1081

Price Chart

Track all markets on TradingView
LIAN
LianBio ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.28 52WK RANGE 0.35

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.87
+0.21%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 MACK
MACK
Merrimack Pharmaceuticals, Inc.
$15.15
+0.10%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message